RYBREVANT FASPRO™
(amivantamab and hyaluronidase-lpuj)
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj)
Study summaries
OrigAMI-4 cohort 1 study
*New data regarding investigational use (per Food and Drug Administration guidance).
Additional resources
Contact our medical experts for your inquiry about RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj)
- Call me now
- Live chatMonday-Friday 9AM - 04:30PM ET
- Live videoMonday-Friday 9AM - 04:30PM ET
- Locate my MSL
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.